[1]
Mardhiyah Fithriana Mufti, Diana Laila Ramatillah, and Sylvia Rizky Prima, “Effectiveness, Safety, and Cost-Effectiveness of the Tenofovir/Lamivudine/Dolutegravir (TLD) Regimen Compared to Tenofovir/Lamivudine/Efavirenz (TLE) in HIV Patients: A Narrative Review”, MODERN, vol. 5, no. 4, pp. 581–600, Aug. 2026.